# SparingVision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sparingvision

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.sparingvision.com
- Total disclosed funding: $57M
- Latest round: Series B (Oct 10, 2022)
- Investors on record: 7

## About

Founded in 2016 and based in Paris, France, SparingVision SAS is a biotechnology company that develops SPVN06, a gene therapy-based approach used for treating inherited retinal diseases such as Retinitis Pigmentosa (RP).

## Funding rounds

- Series B, Oct 10, 2022, $29M — Ysios Capital Partners, Bpifrance, University of Pittsburgh Medical Center, Foundation Fighting Blindness, 4BIO Capital Partners, Jeito Capital, Retinal Degeneration Fund
- Series A, Dec 15, 2020, $27M — Ysios Capital Partners, University of Pittsburgh Medical Center, Foundation Fighting Blindness, Bpifrance, 4BIO Capital Partners, Jeito Capital

## Investors

- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A, Series B
- University of Pittsburgh Medical Center — Series A, Series B
- Foundation Fighting Blindness — Series A, Series B
- Bpifrance — Series A, Series B
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series A, Series B
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A, Series B
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series B